A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma (MORPHEUS-UC)
The MORPHEUS-UC study is trying out different combinations of existing and new drug treatments for a type of bladder cancer called urothelial carcinoma (UC). This study is designed to see how effective these new combinations are at treating the cancer, whether it's grown into the bladder muscle or spread to other parts of the body. Researchers will also be carefully monitoring for any unwanted side effects of the medicines. This is an early phase (Phase I/II) of clinical research, meaning it’s one of the first times these specific combinations are being tested in a larger group of people. The ultimate goal is to find better and safer ways to treat this cancer.
At a glance
What is this study about?
This study, called MORPHEUS-UC, is focused on a type of cancer that starts in the lining of the bladder, known as urothelial carcinoma (UC). Doctors are always looking for better ways to treat this cancer, and this study explores new combinations of medicines. Think of it like trying out different ingredients together to make a new, more effective recipe. The medicines being tested include Tiragolumab, Tecentriq, Cisplatin, and Gemcitabine. Some of these are newer drugs that help your body's immune system fight cancer, while others are standard chemotherapy treatments.
This is a 'Phase Ib/II' study. Phase I helps researchers find the safest dose of a new treatment and understand how it works in the body. Phase II looks at whether the treatment is effective against the cancer. By combining these phases, researchers can quickly learn more about both the safety and effectiveness of these new combinations for people with urothelial carcinoma.
The main goals of this study are to see how well the treatments shrink the cancer or make it disappear completely. For people whose cancer has spread, they'll check if the tumours shrink. For those whose cancer has grown into the bladder muscle but hasn't spread, they'll look to see if all signs of cancer are gone after treatment. They will also carefully watch for any side effects the treatments might cause, to make sure the new combinations are as safe as possible for patients.
Key takeaways
- The study tests new drug combinations for bladder cancer.
- It aims to find out how effective these treatments are and if they are safe.
- The treatments involve different types of medicines, including immune therapies and chemotherapy.
- Regular check-ups, blood tests, and scans are part of participating.
- You can leave the study at any time if you change your mind.
Who may be eligible?
To be part of this study, you need to be at least 18 years old. Both men and women can take part. There will be other specific health requirements that the study doctors will check to make sure the study is a good fit for you.
These checks are important. They help make sure the treatments are as safe as possible for everyone in the study. They also ensure that the results of the study are clear and can help future patients.
Your doctor will discuss all the detailed requirements with you to see if this study could be an option. Don't worry if you don't fit all the criteria; there are many other studies available.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Have you been diagnosed with urothelial carcinoma (a type of bladder cancer)?
- Are you able to attend regular hospital appointments for treatment and check-ups?
- Are you prepared to discuss your full medical history with the study doctors?
What does participation involve?
If you decide to join this study, you'll be part of a team effort to find better treatments for bladder cancer. While the exact details will be explained by the study team, typically, participating in a clinical trial involves a series of hospital visits for treatments and check-ups. You will receive one or more of the study medications, given either by injection or through a drip, over a period of time.
During your visits, you'll have regular medical checks, blood tests, and scans (like CT scans) to see how the treatment is working and to monitor your general health. You will also be asked to report any side effects you experience. The duration of treatment and how long you'll be followed up will depend on the study plan and your individual response. Your study doctor and nurse will explain everything clearly, including how often you'll need to visit and for how long.
Potential risks and benefits
Locations (3)
- —UnverifiedFrance
- —UnverifiedGreece
- —UnverifiedSpain
Common questions
What is urothelial carcinoma?
It's a type of cancer that starts in the cells lining your bladder, but can sometimes be found in other parts of the urinary system.
What does 'Phase Ib/II' mean?
It means this study is looking at both the safety of the new treatment combinations and how well they work against the cancer.
Will I know which treatment I'm getting?
Because this is an 'open-label' study, you and your doctors will know which specific treatment combination you are receiving.
What kind of tests will I have?
You'll have regular blood tests, scans (like CT scans), and physical exams to monitor your health and the cancer.
Can I stop being in the study if I want to?
Yes, you can leave the study at any time, for any reason, without it affecting your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.